Efficacy and Safety of Fexuprazan‐Based Modified High‐Dose Dual Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial
Helicobacter · 2026-05 · 31 (3)
DOI: 10.1111/hel.70146 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, online erschienen am 08.06.2026. Verfasst von Ji Yong Ahn und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. Hauptthemen laut MEDLINE: Helicobacter Infections, Anti-Bacterial Agents, Helicobacter pylori, Proton Pump Inhibitors. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Aims The eradication efficacy of proton pump inhibitor (PPI)–based standard triple therapy (STT) for Helicobacter pylori infection has declined in Korea, largely because of increasing clarithromycin resistance. High‐dose dual therapy (HDDT) using potent acid suppression represents a promising clarithromycin‐sparing strategy. This study evaluated the efficacy and safety of fexuprazan‐based modified HDDT (m‐HDDT) including bismuth, compared with conventional PPI‐based STT as first‐line eradication therapy.
Methods
This prospective, multicenter, randomized, open‐label, non‐inferiority trial was conducted at eight tertiary hospitals in Korea. Treatment‐naïve adults with confirmed H. pylori infection were randomized to receive either m‐HDDT (fexuprazan 40 mg twice daily, amoxicillin 1000 mg three times daily, and bismuth subcitrate potassium 300 mg three times daily) or STT (lansoprazole 30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg, all twice daily) for 14 days. Eradication was assessed by urea breath test 4–8 weeks after therapy. The primary endpoint was the eradication rate in the full analysis set (FAS), with a prespecified non‐inferiority margin of −10%. Safety and compliance were evaluated as secondary outcomes.
Results
In total, 196 patients were included in the FAS (m‐HDDT, n = 96; STT, n = 100). Helicobacter pylori eradication was achieved in 81.3% of patients in the m‐HDDT group and 79.0% in the STT group, demonstrating non‐inferiority of m‐HDDT (one‐sided Wald test, p = 0.0158). Per‐protocol analysis yielded consistent results ( p = 0.0215). Drug compliance was high in both groups, with mean compliance rates of 97.0% in the m‐HDDT group and 99.0% in the STT group; more than 95% of patients in each group achieved ≥ 80% compliance. The incidence of treatment‐emergent adverse events was comparable between groups (16.7% vs. 14.0%); most events consisted of mild gastrointestinal symptoms. No serious adverse events or treatment discontinuations due to adverse events were observed in either group.
Conclusions
Fexuprazan‐based m‐HDDT with bismuth was non‐inferior to PPI‐based STT for H. pylori eradication and demonstrated comparable safety and excellent compliance. This clarithromycin‐sparing regimen can be considered an alternative treatment option in regions with high macrolide resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
- Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.
- Department of Medicine, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, Seoul, South Korea.
- Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.
- Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea.
ORCID-Profile: Ji Yong Ahn, Ki-Nam Shim, Jung-Ho Park, Sang Gyun Kim, Jeong Hwan Kim, Jeong Seop Moon, Young Hoon Youn, Jae J Kim
Zitieren
APA
Ahn, J. Y., Shim, K. N., Park, J. H., Kim, S. G., Kim, J. H., Moon, J. S., Youn, Y. H., & Kim, J. J. (2026). Efficacy and Safety of Fexuprazan‐Based Modified High‐Dose Dual Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial. Helicobacter, 31(3). https://doi.org/10.1111/hel.70146
Vancouver
Ahn JY, Shim KN, Park JH, Kim SG, Kim JH, Moon JS, et al. Efficacy and Safety of Fexuprazan‐Based Modified High‐Dose Dual Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial. Helicobacter. 2026;31(3). doi:10.1111/hel.70146
BibTeX
@article{Ahn2026,
author = {Ahn, Ji Yong and Shim, Ki-Nam and Park, Jung-Ho and Kim, Sang Gyun and Kim, Jeong Hwan and Moon, Jeong Seop and Youn, Young Hoon and Kim, Jae J},
title = {Efficacy and Safety of Fexuprazan‐Based Modified High‐Dose Dual Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial},
journal = {Helicobacter},
year = {2026},
volume = {31},
number = {3},
doi = {10.1111/hel.70146}
}
EUVIMED